Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorFundacion Clinic per a la Recerca Biomédica

About this trial

Study to evaluate the diagnostic precision of ICG and 99mTc nanocolloid albumin in sentinel lymph node detection in early ovarian epithelial cancer.

Eligibility criteria

Qualifiers

Patients with adnexal mass diagnosed with high suspicion of malignancy that will undergo intraoperative biopsy or patients with already diagnosed epithelial cancer in early stages in a previous surgery and confirmed by pathology with complete staging indicated.

Absence of retroperitoneal ganglionary affectation and metastatic disease evaluated by preoperative imaging techniques.

Signing of informed consent by the patient or relative in charge.

Women with childbearing potential must compromise to use highly effective contraceptive methods (partner vasectomized, sexual abstinence) until the end of the study (last study visit).

Disqualifiers

Patients <18 years

Pregnancy or breastfeeding

Epithelial ovarian tumors stage FIGO III or IV.

Impossibility to obtain a biopsy from the tumor.

Trial design

Treatments tested in this trial

  • 99mTC nanocolloid albumin injection
  • ICG injection

Treatment groups

62 Participants
are divided into 1 treatment group